The Joint Program Executive Office for Chemical and Biological Defense (Medical Countermeasures Systems) Chemical Defense Pharmaceutical Division is seeking information on the […] More
In the past decade, there has been an increase in infectious disease outbreaks. The most notable of these was the West Africa […] More
Enzychem Lifesciences, a global biopharmaceutical company focusing on innovative medical countermeasure development, will present at Biotech Showcase™ 2019 investor conference, to be […] More
An ongoing Ebola outbreak in a war-torn region of the Democratic Republic of Congo is already the second-largest Ebola outbreak in history, […] More
To prepare for radiological and nuclear emergencies, the U.S. Department of Health and Human Services (HHS) will work with Argentum Medical, LLC […] More
Under a new three-year, $11.9 million contract with the U.S. federal government, MediWound Ltd. will advance the development of NexoBrid as a […] More
The Defense Logistics Agency Troop Support has a requirement for the supply of Antidote Treatment Nerve Agent Auto-Injector (ATNAA), NSN 6505-01-362-7427. The […] More
Accelerator Life Science Partners, a Seattle-based life sciences investment fund and umbrella company, unveiled its newest company this week. Proniras Corporation was created to develop […] More
There’s now a new medical countermeasure (MCM) available in the United States in the event of radiological or nuclear emergency. The FDA […] More
Despite the proven interesting features of some biocompatible Metal-Organic Framework nanocarriers in the encapsulation and release of many different therapeutic molecules, nerve […] More
Pluristem Therapeutics Inc., developer of placenta-based cell therapy products, has announced that a pilot study of the company’s PLX-R18 cell therapy will […] More
The U.S. Army has released a competitive solicitation to establish an agreement with a single new or established consortium to develop and […] More